Stay updated on Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov site revision changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe IMMULAB study record is displayed with details on pembrolizumab combined with local ablation for hepatocellular carcinoma, including participant criteria, study design, outcome measures, and record dates.SummaryDifference61%

- Check22 days agoChange DetectedThe site revision identifier changed from v3.7.2 to v3.8.0 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA banner announces NIH website updates and says that some NIH content may use “Super Intelligence” (SI) instead of “Artificial Intelligence” (AI) during the transition.SummaryDifference1%

- Check36 days agoChange DetectedThe footer now displays site revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check43 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.